A cancer therapy may shrink the tumor of a patient, and the patient may feel better. But unseen on a CT scan or MR image, some of the cells are undergoing ominous changes. Fueled by new genetic changes due to cancer therapy itself, these rogue cells are becoming very large with twice or quadruple the number of chromosomes found in healthy cells. Some of the cells may grow to eight, 16 or even 32 times the correct number. Quickly, they will become aggressive and resistant to treatment. They will eventually cause cancer recurrence.
Daruka Mahadevan, MD, PhD, professor and chief of the Division of Hematology-Oncology in the Long School of Medicine at UT Health San Antonio, has studied this progression for 20 years. In a paper published in April 2020 in the journal Trends in Cancer, he and co-author Gregory C. Rogers, PhD, explain a rationale for stopping it.
"When you give therapy, some cells don't die," explained Dr. Mahadevan, leader of hematology and medical oncology care at the Mays Cancer Center, home to UT Health San Antonio MD Anderson. "These cells don't die because they've acquired a double complement of the normal chromosomes plus other genetic changes. Many types of chemotherapy actually promote this."
Dr. Mahadevan found that two cancer-causing genes, called c-Myc and BCL2, are operative in "double-hit" high-grade lymphomas, which are incurable. "These genes are part of the problem, because when they are present, they help the lymphoma cells to live longer and prime them to become large cells with treatment," he said.
Although the drugs seem to be working, once therapy is stopped, the large rogue cells (called tetraploid cells) start to divide again and become smaller but faster-growing cells, driven by c-Myc and BCL2.
"It's a double hit, a double whammy," Dr. Mahadevan said.
To counter this, Dr. Mahadevan seeks to find drugs that prevent or treat the rogue cells' acquisition of multiple chromosomes. He has identified a small-molecule inhibitor that shows promise in cell experiments in the laboratory. "We have data to show that it works," he said.
A drug that suppresses large cells with multiple copies of chromosomes could be used in combination with existing chemotherapies to prevent large cell resistance, not only in lymphoma but in many other types of cancer, he said.
Funding for Dr. Mahadevan was from the SWOG Cancer Research Network's Hope Foundation for Cancer Research, the National Cancer Institute Lymphoma Specialized Programs of Research Excellence (SPORE) and a National Cancer Institute Cancer Center Support Grant. Dr. Mahadevan occupies the Mays Family Foundation Distinguished Chair in Oncology at UT Health San Antonio. Dr. Rogers is associate professor in the University of Arizona College of Medicine.
Janus Face of Drug-Induced Tetraploidy in Non-Hodgkin Lymphoma
Daruka Mahadevan, Gregory C. Rogers
First published: April 11, 2020
The Long School of Medicine at The University of Texas Health Science Center at San Antonio is named for Texas philanthropists Joe R. and Teresa Lozano Long. The school is the largest educator of physicians in South Texas, many of whom remain in San Antonio and the region to practice medicine. The school teaches more than 900 students and trains 800 residents each year. As a beacon of multicultural sensitivity, the school annually exceeds the national medical school average of Hispanic students enrolled. The school's clinical practice is the largest multidisciplinary medical group in South Texas with 850 physicians in more than 100 specialties. The school has a highly productive research enterprise where world leaders in Alzheimer's disease, diabetes, cancer, aging, heart disease, kidney disease and many other fields are translating molecular discoveries into new therapies. The Long School of Medicine is home to a National Cancer Institute-designated cancer center known for prolific clinical trials and drug development programs, as well as a world-renowned center for aging and related diseases.
The University of Texas Health Science Center at San Antonio, also referred to as UT Health San Antonio, is one of the country's leading health sciences universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 37,000 alumni who are leading change, advancing their fields, and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways "We make lives better®," visit http://www.uthscsa.edu.
The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is one of only four National Cancer Institute-designated Cancer Centers in Texas. provides leading-edge cancer care, propels innovative cancer research and educates the next generaThe Mays Cancer Centertion of leaders to end cancer in South Texas. Visit UTHealthsaMDAnderson.org.
Trends in Cancer